Skip to main content
SpringerLink
Log in

Molecular Diagnostics: Translation from Discovery to Clinical Practice

  • Chapter
  • First Online:
Molecular Pathology in Cancer Research

  • 1084 Accesses

Abstract

Over the past decade, there has been broad publicity and discussions over the potential of “personalized medicine” to transform clinical practice in oncology. In its broad definition, personalized medicine in oncology refers to the use of biomarkers to make decisions such as the type of therapies, prognosis, and extent of monitoring of disease progression. As such, oncologists have been practicing personalized medicine throughout modern medicine where patients are treated according to clinical staging and the current understanding of specific cancer behaviors. It may be argued that even chemotherapy is personalized, not only in terms of using different chemotherapeutics for different cancer types but also for the concept of using anti-proliferation cytotoxic drugs against highly, uncontrolled proliferative cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm [Pathology “Panel”].

  2. 2.

    http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm [Pathology “Advisory Committee”].

  3. 3.

    http://www.agendia.com/healthcare-professionals/breast-cancer/current-clinical-trials/.

  4. 4.

    http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.

  5. 5.

    http://www.fda.gov/scienceresearch/specialtopics/personalizedmedicine/default.htm.

  6. 6.

    http://www.fda.gov/medicaldevices/productsandmedicalprocedures/ucm407296.htm.

  7. 7.

    http://www.regulations.gov/#!documentDetail;D=FDA-2011-D-0360-0002.

  8. 8.

    http://www.regulations.gov/#!documentDetail;D=FDA-2011-D-0357-0002.

  9. 9.

    http://euapm.eu/.

  10. 10.

    http://ec.europa.eu/health/human-use/personalised-medicine/index_en.htm.

References

  1. Augenlicht LH, Wahrman MZ, Halsey H, Anderson L, Taylor J, Lipkin M (1987) Expression of cloned sequences in biopsies of human colonic tissue and in colonic carcinoma cells induced to differentiate in vitro. Cancer Res 47(22):6017–6021

    CAS  PubMed  Google Scholar 

  2. Augenlicht LH, Taylor J, Anderson L, Lipkin M (1991) Patterns of gene expression that characterize the colonic mucosa in patients at genetic risk for colonic cancer. Proc Natl Acad Sci U S A 88(8):3286–3289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schena M, Shalon D, Davis RW, Brown PO (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270(5235):467–470

    Article  CAS  PubMed  Google Scholar 

  4. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW (1996) Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A 93(20):10614–10619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Drmanac R, Drmanac S, Labat I, Crkvenjakov R, Vicentic A, Gemmell A (1992) Sequencing by hybridization: towards an automated sequencing of one million M13 clones arrayed on membranes. Electrophoresis 13(8):566–573

    Article  CAS  PubMed  Google Scholar 

  6. Drmanac S, Drmanac R (1994) Processing of cDNA and genomic kilobase-size clones for massive screening, mapping and sequencing by hybridization. Biotechniques 17(2):328–329, 332–326

    CAS  PubMed  Google Scholar 

  7. Drmanac S, Stavropoulos NA, Labat I, Vonau J, Hauser B, Soares MB, Drmanac R (1996) Gene-representing cDNA clusters defined by hybridization of 57,419 clones from infant brain libraries with short oligonucleotide probes. Genomics 37(1):29–40. doi:10.1006/geno.1996.0517

    Article  CAS  PubMed  Google Scholar 

  8. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL (1996) Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14(13):1675–1680. doi:10.1038/nbt1296-1675

    Article  CAS  PubMed  Google Scholar 

  9. Editorial (1996) To affinity … and beyond! Nat Genet 14(4):367–370. doi:10.1038/ng1296-367

  10. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258(5083):818–821

    Article  CAS  PubMed  Google Scholar 

  11. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO (1999) Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23(1):41–46. doi:10.1038/12640

    Article  CAS  PubMed  Google Scholar 

  12. Lueking A, Horn M, Eickhoff H, Bussow K, Lehrach H, Walter G (1999) Protein microarrays for gene expression and antibody screening. Anal Biochem 270(1):103–111. doi:10.1006/abio.1999.4063

    Article  CAS  PubMed  Google Scholar 

  13. Michael KL, Taylor LC, Schultz SL, Walt DR (1998) Randomly ordered addressable high-density optical sensor arrays. Anal Chem 70(7):1242–1248

    Article  CAS  PubMed  Google Scholar 

  14. Kuhn K, Baker SC, Chudin E, Lieu MH, Oeser S, Bennett H, Rigault P, Barker D, McDaniel TK, Chee MS (2004) A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res 14(11):2347–2356. doi:10.1101/gr.2739104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14(4):457–460. doi:10.1038/ng1296-457

    Article  CAS  PubMed  Google Scholar 

  16. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91(20):1758–1764

    Article  CAS  PubMed  Google Scholar 

  17. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154(4):981–986. doi:10.1016/S0002-9440(10)65349-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96(16):9212–9217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR Jr, Elkahloun AG (1999) In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 59(22):5656–5661

    CAS  PubMed  Google Scholar 

  20. Mir KU (2000) The hypothesis is there is no hypothesis. The Microarray Meeting, Scottsdale, Arizona, USA, 22–25 September 1999. Trends Genet 16(2):63–64

    Article  CAS  PubMed  Google Scholar 

  21. Debouck C, Goodfellow PN (1999) DNA microarrays in drug discovery and development. Nat Genet 21(1 Suppl):48–50. doi:10.1038/4475

    Article  CAS  PubMed  Google Scholar 

  22. Gray JW, Collins C (2000) Genome changes and gene expression in human solid tumors. Carcinogenesis 21(3):443–452

    Article  CAS  PubMed  Google Scholar 

  23. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439):531–537

    Article  CAS  PubMed  Google Scholar 

  24. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093

    Article  CAS  PubMed  Google Scholar 

  25. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874. doi:10.1073/pnas.191367098

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536. doi:10.1038/415530a

    Google Scholar 

  27. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. doi:10.1056/NEJMoa041588

    Article  CAS  PubMed  Google Scholar 

  28. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB (2004) Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164(1):35–42. doi:10.1016/S0002-9440(10)63093-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S (2005) Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11(24 Pt 1):8623–8631. doi:10.1158/1078-0432.CCR-05-0735

    Article  CAS  PubMed  Google Scholar 

  30. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. doi:10.1200/JCO.2008.18.1370

    Article  PubMed  PubMed Central  Google Scholar 

  31. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, He X, Palazzo JP, Olopade OI, Szabo A, Perou CM, Bernard PS (2006) Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8(2):R23. doi:10.1186/bcr1399

    Article  PubMed  PubMed Central  Google Scholar 

  32. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068. doi:10.1038/nature07385

    Article  Google Scholar 

  33. International Cancer Genome Consortium (2010) International network of cancer genome projects. Nature 464(7291):993–998. doi:10.1038/nature08987

    Article  Google Scholar 

  34. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370(14):1287–1297. doi:10.1056/NEJMoa1311194

    Article  CAS  PubMed  Google Scholar 

  35. Blumencranz P, Whitworth PW, Deck K, Rosenberg A, Reintgen D, Beitsch P, Chagpar A, Julian T, Saha S, Mamounas E, Giuliano A, Simmons R (2007) Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg 194(4):426–432. doi:10.1016/j.amjsurg.2007.07.008

    Article  PubMed  Google Scholar 

  36. Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, Buturovic L, Henner WD (2011) Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 13(1):48–56. doi:10.1016/j.jmoldx.2010.11.001

    Article  PubMed  PubMed Central  Google Scholar 

  37. Handorf CR, Kulkarni A, Grenert JP, Weiss LM, Rogers WM, Kim OS, Monzon FA, Halks-Miller M, Anderson GG, Walker MG, Pillai R, Henner WD (2013) A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol 37(7):1067–1075. doi:10.1097/PAS.0b013e31828309c4

    Article  PubMed  Google Scholar 

  38. Nystrom SJ, Hornberger JC, Varadhachary GR, Hornberger RJ, Gutierrez HR, Henner DW, Becker SH, Amin MB, Walker MG (2012) Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget 3(6):620–628

    Article  PubMed  PubMed Central  Google Scholar 

  39. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10):1671–1676. doi:10.1200/JCO.2008.20.2119

    Article  PubMed  Google Scholar 

  40. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28(10):1677–1683. doi:10.1200/JCO.2009.23.7610

    Article  PubMed  PubMed Central  Google Scholar 

  41. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101(21):1446–1452. doi:10.1093/jnci/djp335

    Article  PubMed  PubMed Central  Google Scholar 

  42. Ahern TP, Hankinson SE (2011) Re: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 103(20):1558–1559. doi:10.1093/jnci/djr327, author reply 1559–1560

    Article  PubMed  Google Scholar 

  43. Ingoldsby H, Webber M, Wall D, Scarrott C, Newell J, Callagy G (2013) Prediction of oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis. Breast 22(5):879–886. doi:10.1016/j.breast.2013.04.008

    Article  PubMed  Google Scholar 

  44. Milburn M, Rosman M, Mylander C, Tafra L (2013) Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed? Breast J 19(4):357–364. doi:10.1111/tbj.12126

    Article  PubMed  Google Scholar 

  45. Gage MM, Rosman M, Mylander WC, Giblin E, Kim HS, Cope L, Umbricht C, Wolff AC, Tafra L (2015) A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay. Clin Breast Cancer. doi:10.1016/j.clbc.2015.04.006

    PubMed  PubMed Central  Google Scholar 

  46. Sun Z, Prat A, Cheang MC, Gelber RD, Perou CM (2015) Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of nonluminal subtypes-waiting for TAILORx and RxPONDER. Ann Oncol 26(1):70–74. doi:10.1093/annonc/mdu493

    Article  CAS  PubMed  Google Scholar 

  47. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA, Quale C (2013) Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 14:690. doi:10.1186/1471-2164-14-690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. You YN, Rustin RB, Sullivan JD (2015) Oncotype DX colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: a review of the evidence. Surg Oncol 24(2):61–66. doi:10.1016/j.suronc.2015.02.001

    Article  PubMed  Google Scholar 

  49. Nguyen B, Cusumano PG, Deck K, Kerlin D, Garcia AA, Barone JL, Rivera E, Yao K, de Snoo FA, van den Akker J, Stork-Sloots L, Generali D (2012) Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol 19(10):3257–3263. doi:10.1245/s10434-012-2561-6

    Article  PubMed  Google Scholar 

  50. Cusumano PG, Generali D, Ciruelos E, Manso L, Ghanem I, Lifrange E, Jerusalem G, Klaase J, de Snoo F, Stork-Sloots L, Dekker-Vroling L, Lutke Holzik M (2014) European inter-institutional impact study of MammaPrint. Breast 23(4):423–428. doi:10.1016/j.breast.2014.02.011

    Article  CAS  PubMed  Google Scholar 

  51. Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retel VP, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R, Dubsky P (2014) The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer. Br J Cancer 111(5):837–842. doi:10.1038/bjc.2014.339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Maak M, Simon I, Nitsche U, Roepman P, Snel M, Glas AM, Schuster T, Keller G, Zeestraten E, Goossens I, Janssen KP, Friess H, Rosenberg R (2013) Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg 257(6):1053–1058. doi:10.1097/SLA.0b013e31827c1180

    Article  PubMed  Google Scholar 

  53. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J (2013) Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31(22):2783–2790. doi:10.1200/JCO.2012.46.1558

    Article  PubMed  Google Scholar 

  54. Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO, Austrian B, Colorectal Cancer Study Group (2014) Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25(2):339–345. doi:10.1093/annonc/mdt494

    Article  CAS  PubMed  Google Scholar 

  55. Martin M, Gonzalez-Rivera M, Morales S, de la Haba-Rodriguez J, Gonzalez-Cortijo L, Manso L, Albanell J, Gonzalez-Martin A, Gonzalez S, Arcusa A, de la Cruz-Merino L, Rojo F, Vidal M, Galvan P, Aguirre E, Morales C, Ferree S, Pompilio K, Casas M, Caballero R, Goicoechea U, Carrasco E, Michalopoulos S, Hornberger J, Prat A (2015) Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. Curr Med Res Opin 31(6):1129–1137. doi:10.1185/03007995.2015.1037730

    Article  CAS  PubMed  Google Scholar 

  56. Prat A, Galvan P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Alvarez M, Diaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramon YCS, Peg V, Alba E (2015) Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the Prosigna assay. Clin Cancer Res. doi:10.1158/1078-0432.CCR-15-0630

    Google Scholar 

  57. Phillips KA, Van Bebber S, Issa AM (2006) Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov 5(6):463–469. doi:10.1038/nrd2033

    Article  CAS  PubMed  Google Scholar 

  58. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA (2013) Criteria for the use of omics-based predictors in clinical trials. Nature 502(7471):317–320. doi:10.1038/nature12564

    Google Scholar 

  59. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA (2013) Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med 11:220. doi:10.1186/1741-7015-11-220

  60. Editorial (2014) NCI issues omics checklist for tests. Cancer Discov 4(2):OF6. doi:10.1158/2159-8290.CD-NB2013-157

  61. Hayes DF (2013) omics-based personalized oncology: if it is worth doing, it is worth doing well! BMC Med 11:221. doi:10.1186/1741-7015-11-221

  62. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180–1184. doi:10.1093/jnci/dji237

    Google Scholar 

  63. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2(8):416–422

    Google Scholar 

  64. Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9(5), e1001216. doi:10.1371/journal.pmed.1001216

    Article  PubMed  PubMed Central  Google Scholar 

  65. Jaffe S (2015) Planning for US Precision Medicine Initiative underway. Lancet 385(9986):2448–2449. doi:10.1016/S0140-6736(15)61124-2

    Article  PubMed  Google Scholar 

  66. Ashley EA (2015) The precision medicine initiative: a new national effort. JAMA 313(21):2119–2120. doi:10.1001/jama.2015.3595

    Article  CAS  PubMed  Google Scholar 

  67. Brand A, Lal JA; Public Health Genomics European Network (2012) European Best Practice Guidelines for quality assurance, provision and use of genome-based information and technologies: the 2012 declaration of Rome. Drug Metabol Drug Interact 27(3):177–182. doi:10.1515/dmdi-2012-0026

  68. Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23(9):2020–2027. doi:10.1200/JCO.2005.01.112

    Article  PubMed  Google Scholar 

  69. Freidlin B, McShane LM, Polley MY, Korn EL (2012) Randomized phase II trial designs with biomarkers. J Clin Oncol 30(26):3304–3309. doi:10.1200/JCO.2012.43.3946

    Article  PubMed  PubMed Central  Google Scholar 

  70. Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA (2015) Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 20(5):474–482. doi:10.1634/theoncologist.2014-0372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. de Gramont A, Watson S, Ellis LM, Rodon J, Tabernero J, de Gramont A, Hamilton SR (2015) Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 12(4):197–212. doi:10.1038/nrclinonc.2014.202

    Article  PubMed  Google Scholar 

  72. Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG (2013) From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst 105(19):1441–1456. doi:10.1093/jnci/djt209

    Article  PubMed  PubMed Central  Google Scholar 

  73. Bertotti A, Trusolino L (2013) From bench to bedside: does preclinical practice in translational oncology need some rebuilding? J Natl Cancer Inst 105(19):1426–1427. doi:10.1093/jnci/djt253

    Article  PubMed  Google Scholar 

  74. Biophoenix (2008) The convergence of biomarkers and diagnostics: therapy area analyses, key products and future trend. Business Insights Ltd, London

    Google Scholar 

  75. Falkingbridge S (2009) Expanding applications of personalized medicine: use of biomarkers in prognostic, predictive and pharmacogenetic tests in a targeted approach. Business Insights Ltd, London

    Google Scholar 

  76. Aldridge S (2009) Innovations in oncology diagnostics: technological advances, growth opportunities and future market outlook. Business Insights Ltd, London

    Google Scholar 

  77. Nolen BM, Lokshin AE (2013) Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther 17(3):139–146

    Google Scholar 

  78. Cheng WY, Ou Yang TH, Anastassiou D (2013) Biomolecular events in cancer revealed by attractor metagenes. PLoS Comput Biol 9(2), e1002920. doi:10.1371/journal.pcbi.1002920

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Al-Ejeh F, Simpson PT, Sanus JM, Klein K, Kalimutho M, Shi W, Miranda M, Kutasovic J, Raghavendra A, Madore J, Reid L, Krause L, Chenevix-Trench G, Lakhani SR, Khanna KK (2014) Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis 3, e100. doi:10.1038/oncsis.2014.14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Evans BJ, Burke W, Jarvik GP (2015) The FDA and genomic tests—getting regulation right. N Engl J Med 372(23):2258–2264. doi:10.1056/NEJMsr1501194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Litwack ED, Mansfield E, Shuren J (2015) The FDA and genetic testing. N Engl J Med 372(23):2273–2274. doi:10.1056/NEJMc1504604

    Article  CAS  PubMed  Google Scholar 

  82. Collins FS, Hamburg MA (2013) First FDA authorization for next-generation sequencer. N Engl J Med 369(25):2369–2371. doi:10.1056/NEJMp1314561

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Lu JT, Campeau PM, Lee BH (2014) Genotype-phenotype correlation—promiscuity in the era of next-generation sequencing. N Engl J Med 371(7):593–596. doi:10.1056/NEJMp1400788

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Personalised Medicine, QIMR Berghofer Medical Research Institute, Bancroft Building, 300 Herston Road, Herston, QLD, 4006, Australia

    Fares Al-Ejeh

  2. Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, Garscube Estate, Switchback Road, Bearsden, Glasgow, Scotland, G61 1BD, UK

    Andrew V. Biankin

Authors
  1. Fares Al-Ejeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew V. Biankin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Fares Al-Ejeh or Andrew V. Biankin .

Editor information

Editors and Affiliations

  1. UQ Centre for Clinical Research, The Royal Brisbane and Women’s Hospital, University of Queensland and Pathology Queensland, Brisbane, Queensland, Australia

    Sunil R. Lakhani

  2. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia

    Stephen B. Fox

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media LLC

About this chapter

Cite this chapter

Al-Ejeh, F., Biankin, A.V. (2016). Molecular Diagnostics: Translation from Discovery to Clinical Practice. In: Lakhani, S., Fox, S. (eds) Molecular Pathology in Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-6643-1_1

Download citation

Publish with us

Policies and ethics

Search

Navigation